A tale of two receptors: insulin and insulin-like growth factor signaling in cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.Breast cancer research and treatment · 2015
   Trial
2. Insulin promotes growth in breast cancer cells through the type I IGF receptor in insulin receptor deficient cells.Experimental cell research · 2024
   Article
3. Inhibiting IGF1R-mediated Survival Signaling in Head and Neck Cancer with the Peptidomimetic SSTNCancer research communications · 2023
   Article
4. IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma.Cancers · 2021
   Article
5. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.NPJ breast cancer · 2021
   Article
6. Metabolic Strategies for Inhibiting Cancer Development.Advances in nutrition (Bethesda, Md.) · 2021
   Review
7. Disrupting Insulin and IGF Receptor Function in Cancer.International journal of molecular sciences · 2021
   Review
8. Development of the phenylpyrazolo[3,4-Theranostics · 2021
   Article
9. Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface.Frontiers in oncology · 2021
   Review
10. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.Hormones & cancer · 2018
    Article
11. Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study.World journal of gastroenterology · 2017
    Article
12. Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer.Frontiers in endocrinology · 2017
    Article
13. Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
14. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma.Annals of surgical oncology · 2016
    Article
15. Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article

Corrections and comments

• Comment on
  Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.2015
• Comment on
  A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.2015

Authors and funding

1 author.

Funding

Abstract

Indexed as